Fig. 1From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationChanges in pulmonary function after 3 months combination therapy. a After 3 months of combination treatment, FEV1 (% predicted) and FVC (% predicted) increased significantly. Percentage of FEV1 and FVC also increased after combination therapy, but the results were not significant. b RV (% predicted) and RV/TLC (% predicted) significantly decreased with combination therapy, whereas TLC (% predicted) did not change. c DLCO significantly improved with combination therapy. *p < 0.05, **p < 0.01 compared with measurements at BOS diagnosisBack to article page